Equity Overview
Price & Market Data
Price: $1.30
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $1,069,805
Daily Volume: 0
Performance Metrics
1 Week: 3.17%
1 Month: -8.45%
3 Months: -74.51%
6 Months: -85.36%
1 Year: -95.17%
YTD: -88.27%
Company Details
Employees: 3
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002 for the treatment of mild traumatic brain injury, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Sarasota, Florida.